Abstract
Leukotriene (LT) B4 is an inflammatory mediator that has been implicated in the pathogenesis of various diseases, including inflammatory bowel disease and psoriasis. As the rate-limiting step for LTB4 production, LTA4 hydrolase represents an attractive target for therapeutic agents that interfere with LTB4 production. In the present study we evaluated a chemically novel compound designated SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl) as an inhibitor of LTA4 hydrolase. Pharmacological comparisons are made to its free acid SC-57461. SC-57461A is a potent competitive inhibitor of recombinant human LTA4 hydrolase when either LTA4(IC50 = 2.5 nM, Ki = 23 nM) or peptide substrates (IC50 = 27 nM) are used. In human whole blood, the IC50 for calcium ionophore-induced LTB4 production was 49 nM, indicative of good cell penetration. Whole blood production of the cyclooxygenase metabolite thromboxane B2 was not affected. SC-57461A was also active in several other species, including mouse, rat, dog, and rhesus monkey. The data indicate that SC-57461A is a potent and selective inhibitor of LTA4 hydrolase.
Footnotes
- Abbreviations:
- LT
- leukotriene
- SC-57461A
- 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl
- LTA4
- 5(S)-trans-5,6-oxido-7,9-trans-11,14-cis-eicosatetraenoic acid
- LTB4
- 5(S),12(R)-dihydroxy-6,14-cis-8,10-trans-eicosatetraenoic acid
- 5-LO
- 5-lipoxygenase
- rhLTA4
- recombinant human leukotriene A4 hydrolase
- ELISA
- enzyme-linked immunosorbent assay
- BSA
- bovine serum albumin
- DMSO
- dimethyl sulfoxide
- RP-HPLC
- reversed phase-high-performance liquid chromatography
- pNA
- p-nitroanilide
- TxB2
- thromboxane B2
- A23187
- calcium ionophore A23187(Calcimycin)
- Received July 17, 2001.
- Accepted November 2, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
